<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38794" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Diabetes Mellitus Screening</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vasavada</surname>
            <given-names>Advait</given-names>
          </name>
          <aff>AIIMS</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Taub</surname>
            <given-names>Leslie Faith M.</given-names>
          </name>
          <aff>New York University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Advait Vasavada declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leslie Faith Taub declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38794.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Screening for any disease is fruitful when there is benefit from its early diagnosis and intervention. This activity discusses the screening for diabetes mellitus, which is&#x000a0;1 of those diseases that affect millions worldwide. Diabetes Mellitus includes&#x000a0;3 groups of diseases: type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes</p>
        <p>
<bold>Type 1 Diabetes</bold>
</p>
        <p>Type I diabetes is diagnosed after hyperglycemia symptoms like polyuria, polydipsia, weight loss, and lethargy. It can also present as diabetic ketoacidosis in resource-constrained areas. Screening for type I diabetes is still in its infancy, although trials with tests for insulin, zinc transporter 8, antibodies to islet cells, IA-2, and GAD65 are underway.<xref ref-type="bibr" rid="article-38794.r1">[1]</xref><xref ref-type="bibr" rid="article-38794.r2">[2]</xref></p>
        <p>
<bold>Type 2 Diabetes</bold>
</p>
        <p>&#x000a0;Type 2 diabetes may initially have few symptoms; however, long-term effects lead to a myriad of different problems late in the course of the disease, leading to debilitating sequelae. More than 30 million people in the US have diabetes.<xref ref-type="bibr" rid="article-38794.r3">[3]</xref>&#x000a0;Due to an initial silent course, it often remains undetected for quite a long time before the appearance of symptoms. The screening for the disease aims at prevention and early treatment with the&#x000a0;assumption that there is a long-term benefit to its identification early in the disease process. The long-term benefit of screening vs. clinically detected diabetes is being explored.<xref ref-type="bibr" rid="article-38794.r4">[4]</xref>&#x000a0;Several studies with&#x000a0;weak evidence suggest the merits of screening tests.<xref ref-type="bibr" rid="article-38794.r5">[5]</xref>&#x000a0;Screening for&#x000a0;type 2 diabetes can&#x000a0;be done by fasting blood sugar, hemoglobin (A1C), glucose tolerance testing, and random plasma sugar. Urine glucose may be useful, but it is an inferior test to screen for diabetes, although research is reconsidering this claim.<xref ref-type="bibr" rid="article-38794.r6">[6]</xref></p>
        <p>The screening is said to be positive if there are&#x000a0;2 abnormal tests from the same sample or&#x000a0;2 separate samples for the first&#x000a0;3 tests below:<xref ref-type="bibr" rid="article-38794.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>HbA1C over 6.5 percent<xref ref-type="bibr" rid="article-38794.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Fasting plasma glucose greater than or equal to 126 mg/dL</p>
          </list-item>
          <list-item>
            <p>2-hour glucose greater than or equal to 200 mg/dL in an oral glucose tolerance test with 75 mg glucose load.</p>
          </list-item>
          <list-item>
            <p>Random blood glucose greater than or equal to 200 mg/dL in symptomatic patients (thirst, polyuria, weight loss, blurry vision)</p>
          </list-item>
        </list>
        <p>For the diagnosis of diabetes mellitus, symptomatic patients require no further tests. HbA1C values can be affected by factors that increase or decrease the RBC lifespan. Anemic states falsely increase HbA1C values, whereas their treatment falsely decreases it.<xref ref-type="bibr" rid="article-38794.r9">[9]</xref> Kidney disease can affect the values and may increase or decrease values based on the treatment the patient is getting.&#x000a0;Erythropoietin can falsely lower HbA1c values. Hemoglobin variants like HbS and HbC also cause variations in HbA1c values.<xref ref-type="bibr" rid="article-38794.r10">[10]</xref>&#x000a0;The US Preventive Services Task Force's recommendation is to&#x000a0;screen&#x000a0;for diabetes between&#x000a0;40 and 70 years who are overweight or obese&#x000a0;and repeat testing every&#x000a0;3 years if results are normal.&#x000a0;</p>
        <p>Risk factors for diabetes include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>HDL &#x0003c; 35 mg/dL or TG &#x0003e; 250 mg/dL</p>
          </list-item>
          <list-item>
            <p>First-degree relative with diabetes</p>
          </list-item>
          <list-item>
            <p>High-risk race/ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)</p>
          </list-item>
          <list-item>
            <p>Asian Americans with a BMI of greater than or equal to 23 kg/m</p>
          </list-item>
          <list-item>
            <p>Women who have delivered a child greater than 9 lbs (4 kg) or with gestational diabetes</p>
          </list-item>
          <list-item>
            <p>HbA1c = 5.7%, impaired fasting glucose or impaired glucose tolerance</p>
          </list-item>
        </list>
        <p>Other: acanthosis nigricans, polycystic ovary syndrome, history of coronary vascular disease, physical inactivity<xref ref-type="bibr" rid="article-38794.r11">[11]</xref><xref ref-type="bibr" rid="article-38794.r7">[7]</xref>&#x000a0;The recommendations for those with a high risk of developing diabetes are candidates for more early/frequent screening, early behavior intervention, and intensive treatment. The recommended interval for the screening of asymptomatic patients is&#x000a0;3 years. The interval can be short in patients who have obesity and other major risk factors for developing diabetes. The American Diabetes Association recommends screening for diabetes in adults aged 45 years or older and screening in persons with multiple risk factors regardless of age. The American Association of Clinical Endocrinologists, American Academy of Family Physicians, Diabetes Australia,&#x000a0;Diabetes UK,&#x000a0;and the Canadian Task Force on Preventive Health Care have recommendations that differ in their approach to screening but acknowledge and stress risk factors compared to an older age.</p>
        <p>
<bold>Gestational Diabetes</bold>
</p>
        <p>Gestational diabetes adversely impacts the lives of both fetus and mother, making screening for it an essential part of obstetric care. Screening is necessary for 1 of the risk factors for diabetes. In addition to the risk factors discussed above, others include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>History of prediabetes (impaired glucose tolerance/fasting glucose, HbA1C&#x0003e;5.7)</p>
          </list-item>
          <list-item>
            <p>Prior history of gestational diabetes</p>
          </list-item>
          <list-item>
            <p>BMI&#x0003e;30 kg/m<sup>2</sup></p>
          </list-item>
          <list-item>
            <p>Family history of diabetes</p>
          </list-item>
          <list-item>
            <p>Multiple gestations</p>
          </list-item>
          <list-item>
            <p>Old maternal age</p>
          </list-item>
          <list-item>
            <p>Glycosuria at the first prenatal visit</p>
          </list-item>
          <list-item>
            <p>History of unexplained miscarriage or malformation</p>
          </list-item>
        </list>
        <p>In the US, all women are screened for gestational diabetes, as most of them have at least&#x000a0;a few of these risk factors. HbA1C and fasting blood glucose have not been found useful for screening gestational diabetes. A glucose tolerance test is helpful in effective screening for this condition.<xref ref-type="bibr" rid="article-38794.r12">[12]</xref>&#x000a0;Two ways are screening for gestational diabetes can be done:</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;One-step method: Glucose tolerance test with 75 mg glucose load (overnight fast required).</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Two-step method: First, a 50 g glucose challenge test, which, if positive, is followed by a confirmatory second 3-hour glucose tolerance test with a 100 g glucose load.</p>
          </list-item>
        </list>
        <p>The 1-step 75 g glucose tolerance test is simpler and widely used. The test is positive if it satisfies any&#x000a0;1 of the following: fasting glucose&#x000a0;&#x02265;92 mg/dL (5.1 mmol/L),&#x000a0;1hr glucose&#x000a0;&#x02265;180 mg/dL (10.0 mmol/L), or 2hr glucose&#x000a0;&#x02265;153 mg/dL&#x000a0;(8.5 mmol/mol)</p>
      </sec>
      <sec id="article-38794.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>There are many ongoing attempts to predict type 1 diabetes mellitus; all are still in the research phases. The level of evidence regarding the usefulness of screening for type 2 diabetes for long-term complications, especially macrovascular complications, has been a matter of debate. There are conflicting studies that show no mortality benefit of screening for diabetes compared to those who receive a diagnosis on a clinical basis. Newer studies dispute this claim as more data for greater than&#x000a0;10 years becomes available in the future.<xref ref-type="bibr" rid="article-38794.r5">[5]</xref>&#x000a0;Although the screening may lead to an increase in patients receiving overtreatment and give rise to issues like polypharmacy, side effects, increased cost, etc, experts believe the benefit achieved from the treatment of this disorder to be far higher.<xref ref-type="bibr" rid="article-38794.r4">[4]</xref><xref ref-type="bibr" rid="article-38794.r13">[13]</xref>&#x000a0;The recommendations are, at present, based upon the different sets of risk factors to determine those who are considered moderate or high risk. Each such recommendation defines high-risk patients differently. As more data emerges, there&#x000a0;may&#x000a0;be more congruency in those definitions. Among the different methods to determine the level of risk of developing diabetes,&#x000a0;1 of the most popular is FINDRISC.<xref ref-type="bibr" rid="article-38794.r14">[14]</xref> Further improvement in such scoring systems could lead to a better selection of patients who undergo screening, leading to improved care at scale. Such methods can bring uniformity in the screening process for diabetes.</p>
      </sec>
      <sec id="article-38794.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>There is compelling evidence&#x000a0;that early treatment of diabetes can reduce microvascular complications of diabetes.<xref ref-type="bibr" rid="article-38794.r15">[15]</xref>&#x000a0;The prompt treatment of the disease has significantly improved mortality, especially related to&#x000a0;vascular disease.<xref ref-type="bibr" rid="article-38794.r5">[5]</xref>&#x000a0;The evidence for the impact of screening for diabetes is increasing. It is considered to be&#x000a0;1 of the more straightforward ways to prevent and reduce morbidity and mortality of this disease. Excess mortality related to type 2 diabetes results from cardiovascular events, and early screening has the potential to allow for early intervention. The UKPDS demonstrated a 14% reduction in&#x000a0;myocardial infarctions for every 1% decrease in HbA1c value.<xref ref-type="bibr" rid="article-38794.r16">[16]</xref>&#x000a0;Gestational diabetes is an identified cause of several adverse outcomes during pregnancy, like pre-eclampsia, macrosomia, birth trauma, perinatal mortality, and neonatal cardiac, respiratory, and metabolic complications.<xref ref-type="bibr" rid="article-38794.r17">[17]</xref> There is also a long-term risk of developing type 1/type 2 diabetes mellitus and cardiovascular disease in the mother, as well as metabolic syndrome, obesity, hypertension, and impaired glucose tolerance in the child. Identifying this early and prompt management has a positive impact on the health of the mother as well as the child.<xref ref-type="bibr" rid="article-38794.r18">[18]</xref></p>
      </sec>
      <sec id="article-38794.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The screening process invariably involves nursing&#x000a0;personnel who usually&#x000a0;obtain finger stick readings and perform the blood draw. Nurse practitioners and certified diabetes educators play a crucial role in education, medication reconciliation, and demonstrating the&#x000a0;proper use of devices and medication. Their active involvement assists the medical team in recognizing the cases that could benefit from screening and assists with early detection.<xref ref-type="bibr" rid="article-38794.r19">[19]</xref>&#x000a0;A&#x000a0;hematologist and the nephrologist&#x000a0;may consult on the validity of a result where multiple factors could affect the test results. For example, a person with anemia or kidney disease could have altered HbA1C values. The endocrinologist&#x000a0;may assist and identify a group of patients who potentially have a higher risk of diabetes and recommend early/more frequent screening, such as those with other autoimmune diseases such as thyroid disease.<xref ref-type="bibr" rid="article-38794.r20">[20]</xref>&#x000a0;Complex cases such as those with cystic fibrosis, HIV, and post-transplant patients can be discussed with an endocrinologist to decide the usefulness of screening in such patients to form an individualized management plan. Hence, a team effort could improve screening outcomes and prevent the diagnosis from going undetected.&#x000a0;</p>
      </sec>
      <sec id="article-38794.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38794&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38794">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38794/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38794">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38794.s6">
        <title>References</title>
        <ref id="article-38794.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Contreras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Boccuzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Ricordi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>2940</fpage>
            <page-range>2940-2956</page-range>
            <pub-id pub-id-type="pmid">28682421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Belle</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Coppieters</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>von Herrath</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Type 1 diabetes: etiology, immunology, and therapeutic strategies.</article-title>
            <source>Physiol Rev</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-118</page-range>
            <pub-id pub-id-type="pmid">21248163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Handelsman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Heile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Burden of Illness in Type 2 Diabetes Mellitus.</article-title>
            <source>J Manag Care Spec Pharm</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>9-a Suppl</issue>
            <fpage>S5</fpage>
            <page-range>S5-S13</page-range>
            <pub-id pub-id-type="pmid">30156443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simmons</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Echouffo-Tcheugui</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sargeant</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Prevost</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Kinmonth</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wareham</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2012</year>
            <month>Nov</month>
            <day>17</day>
            <volume>380</volume>
            <issue>9855</issue>
            <fpage>1741</fpage>
            <page-range>1741-8</page-range>
            <pub-id pub-id-type="pmid">23040422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregg</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geiss</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Albright</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Imperatore</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jun</month>
            <day>16</day>
            <volume>391</volume>
            <issue>10138</issue>
            <fpage>2430</fpage>
            <page-range>2430-2440</page-range>
            <pub-id pub-id-type="pmid">29784146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of urinary glucose for diabetes screening: a reconsideration.</article-title>
            <source>Acta Diabetol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-53</page-range>
            <pub-id pub-id-type="pmid">30159749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <article-title>Introduction: <italic>Standards of Medical Care in Diabetes-2020</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>Suppl 1</issue>
            <fpage>S1</fpage>
            <page-range>S1-S2</page-range>
            <pub-id pub-id-type="pmid">31862741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <source>Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation</source>
            <publisher-name>World Health Organization</publisher-name>
            <publisher-loc>Geneva</publisher-loc>
            <year>2011</year>
            <pub-id pub-id-type="pmid">26158184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarim</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>K&#x000fc;&#x000e7;&#x000fc;kerdo&#x0011f;an</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nay</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Eralp</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ercan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus.</article-title>
            <source>Pediatr Int</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>357</fpage>
            <page-range>357-62</page-range>
            <pub-id pub-id-type="pmid">10453183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mongia</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Rohlfing</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>D'Costa</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Luzzi</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>130</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <page-range>136-40</page-range>
            <pub-id pub-id-type="pmid">18550483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waheed</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Screening for Type II Diabetes Mellitus in the United States: The Present and the Future.</article-title>
            <source>Clin Med Insights Endocrinol Diabetes</source>
            <year>2016</year>
            <volume>9</volume>
            <fpage>19</fpage>
            <page-range>19-22</page-range>
            <pub-id pub-id-type="pmid">27330335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dryden</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muise</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vandermeer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aktary</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Pasichnyk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seida</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Screening and diagnosing gestational diabetes mellitus.</article-title>
            <source>Evid Rep Technol Assess (Full Rep)</source>
            <year>2012</year>
            <month>Oct</month>
            <issue>210</issue>
            <fpage>1</fpage>
            <page-range>1-327</page-range>
            <pub-id pub-id-type="pmid">24423035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez-Gutierrez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonzalez-Gonzalez</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Zu&#x000f1;iga-Hernandez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Benefits and harms of intensive glycemic control in patients with type 2 diabetes.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>Nov</month>
            <day>05</day>
            <volume>367</volume>
            <fpage>l5887</fpage>
            <pub-id pub-id-type="pmid">31690574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuomilehto</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevention of type 2 diabetes - where is the evidence?</article-title>
            <source>East Mediterr Health J</source>
            <year>2014</year>
            <month>Dec</month>
            <day>17</day>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>677</fpage>
            <page-range>677-8</page-range>
            <pub-id pub-id-type="pmid">25601804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valencia</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Florez</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>How to prevent the microvascular complications of type 2 diabetes beyond glucose control.</article-title>
            <source>BMJ</source>
            <year>2017</year>
            <month>Jan</month>
            <day>17</day>
            <volume>356</volume>
            <fpage>i6505</fpage>
            <pub-id pub-id-type="pmid">28096078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marshall</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Flyvbjerg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevention and early detection of vascular complications of diabetes.</article-title>
            <source>BMJ</source>
            <year>2006</year>
            <month>Sep</month>
            <day>02</day>
            <volume>333</volume>
            <issue>7566</issue>
            <fpage>475</fpage>
            <page-range>475-80</page-range>
            <pub-id pub-id-type="pmid">16946335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plows</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Stanley</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>The Pathophysiology of Gestational Diabetes Mellitus.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Oct</month>
            <day>26</day>
            <volume>19</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">30373146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mack</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Tomich</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Gestational Diabetes: Diagnosis, Classification, and Clinical Care.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-217</page-range>
            <pub-id pub-id-type="pmid">28499531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siminerio</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Funnell</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Peyrot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>US nurses' perceptions of their role in diabetes care: results of the cross-national Diabetes Attitudes Wishes and Needs (DAWN) study.</article-title>
            <source>Diabetes Educ</source>
            <year>2007</year>
            <season>Jan-Feb</season>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>152</fpage>
            <page-range>152-62</page-range>
            <pub-id pub-id-type="pmid">17272801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38794.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Thyroid disorders and diabetes. It is common for a person to be affected by both thyroid disease and diabetes.</article-title>
            <source>Diabetes Self Manag</source>
            <year>2007</year>
            <season>Sep-Oct</season>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>80</fpage>
            <page-range>80-2, 85-7</page-range>
            <pub-id pub-id-type="pmid">18046820</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
